Amgen (AMGN) Amortization - Intangibles (2009 - 2012)
Amgen (AMGN) recorded quarterly Amortization - Intangibles of $73.0 million in Q4 2012, down 1.35% quarter-over-quarter from $74.0 million in Q3 2012, and little changed on a YoY basis from $73.0 million in Q1 2012.
Amgen (AMGN) Amortization - Intangibles (2009 - 2012) Analysis & Trends
Amgen's Amortization - Intangibles history runs 4 years deep, the most recent figure standing at $73.0 million for Q4 2012.
- In Q4 2012, Amortization - Intangibles changed 0.0% year-over-year to $73.0 million; the TTM figure through Dec 2012 stood at $294.0 million (changed 0.0% YoY), while the FY2012 annual figure was $294.0 million, changed 0.0% from the prior year.
- Amortization - Intangibles was $73.0 million for Q4 2012 at Amgen, down from $74.0 million in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $74.0 million in Q1 2009 to a low of $73.0 million in Q2 2009.
- Historically, Amortization - Intangibles has averaged $73.5 million across 4 years, with a median of $73.5 million in 2009.
- Biggest YoY gain for Amortization - Intangibles was 0.0% in 2010; the steepest drop was 0.0% in 2010.
- A 4-year view of Amortization - Intangibles shows it stood at $73.0 million in 2009, then changed by 0.0% to $73.0 million in 2010, then changed by 0.0% to $73.0 million in 2011, then changed by 0.0% to $73.0 million in 2012.
- The last three Amortization - Intangibles figures came in at $73.0 million (Q4 2012), $74.0 million (Q3 2012), and $73.0 million (Q2 2012), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 73.00 Mn |
| Sep 30, 2012 | 74.00 Mn |
| Jun 30, 2012 | 73.00 Mn |
| Mar 31, 2012 | 74.00 Mn |
| Dec 31, 2011 | 73.00 Mn |
| Sep 30, 2011 | 74.00 Mn |
| Jun 30, 2011 | 73.00 Mn |
| Mar 31, 2011 | 74.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Sep 30, 2010 | 74.00 Mn |
| Jun 30, 2010 | 73.00 Mn |
| Mar 31, 2010 | 74.00 Mn |
| Dec 31, 2009 | 73.00 Mn |
| Sep 30, 2009 | 74.00 Mn |
| Jun 30, 2009 | 73.00 Mn |
| Mar 31, 2009 | 74.00 Mn |